One PrEP Regimen Linked to Higher Risk of Hypertension, Statin Use Over Another
Use of tenofovir alafenamide fumarate (TAF) for HIV pre-exposure prophylaxis (PrEP) was associated with an increased risk of hypertension and the initiation of statin use within 2 years compared with the use of tenofovir disoproxil fumarate (TDF; Viread), especially for people over age 40, a retrospective cohort study found. In a cohort of patients without […]
Tenofovir, Vaccine Combo Eliminates Mom-to-Child HBV Transmission
Earlier maternal tenofovir disoproxil fumarate (TDF) combined with infant vaccination completely eliminated vertical transmission of chronic hepatitis B virus (HBV) from highly viremic mothers, even without the use of hepatitis B immunoglobulin (HBIg), a randomized trial conducted in China found. At 28 weeks postpartum, mother-to-child transmission was an identical 0% with early maternal TDF therapy […]
Relapse Patterns in Chronic Hep B After Halting Treatment
Chronic hepatitis B patients who discontinued tenofovir disoproxil fumarate (TDF, Viread) after achieving viral suppression had higher rates of clinical relapse compared to those who stopped entecavir, a global retrospective study found. At 6 and 24 months, clinical relapse rates after stopping TDF grew from 31% to 58%, which was significantly higher than after entecavir […]
Tenofovir Treatment Lessened Risk of Severe COVID Infection in HBV
Treatment with tenofovir reduced the risk of severe COVID-19 infection among patients with chronic hepatitis B virus (HBV), a researcher reported. In the database study of adults with HBV already on tenofovir (Biktarvy) or entecavir at 28 Spanish hospitals, patients on tenofovir had a 6% lower risk of developing severe COVID-19 versus 36% of those […]